These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 19633484)

  • 21. A phase II trial of erlotinib monotherapy in pretreated patients with advanced non-small cell lung cancer who do not possess active EGFR mutations: Okayama Lung Cancer Study Group trial 0705.
    Yoshioka H; Hotta K; Kiura K; Takigawa N; Hayashi H; Harita S; Kuyama S; Segawa Y; Kamei H; Umemura S; Bessho A; Tabata M; Tanimoto M;
    J Thorac Oncol; 2010 Jan; 5(1):99-104. PubMed ID: 19898258
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mind your elders: therapeutic implications of epidermal growth factor receptor inhibition in older patients with advanced non-small-cell lung cancer.
    Langer CJ
    J Clin Oncol; 2007 Mar; 25(7):751-3. PubMed ID: 17228017
    [No Abstract]   [Full Text] [Related]  

  • 23. Safety profile of erlotinib in patients with advanced non-small cell lung cancer with chronic renal failure.
    Gridelli C; Maione P; Galetta D; Rossi A
    J Thorac Oncol; 2007 Jan; 2(1):96-8. PubMed ID: 17410020
    [No Abstract]   [Full Text] [Related]  

  • 24. [Tyrosine kinase inhibitor erlotinib (Tarceva) improves survival of patients with multiple previous treatments].
    Krankenpfl J; 2004; 42(5-6):158. PubMed ID: 15527222
    [No Abstract]   [Full Text] [Related]  

  • 25. Erlotinib after failure of gefitinib in patients with advanced non-small cell lung cancer previously responding to gefitinib.
    Vasile E; Tibaldi C; Chella A; Falcone A
    J Thorac Oncol; 2008 Aug; 3(8):912-4. PubMed ID: 18670311
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Erlotinib-associated alopecia in a lung cancer patient.
    Costa DB; Kobayashi S; Schumer ST
    J Thorac Oncol; 2007 Dec; 2(12):1136-8. PubMed ID: 18090591
    [No Abstract]   [Full Text] [Related]  

  • 27. Compassionate use programs or phase IV trials of innovative molecular targeted drugs in lung cancer: deal or no deal?
    Eberhardt W
    J Thorac Oncol; 2010 Oct; 5(10):1495-7. PubMed ID: 20871257
    [No Abstract]   [Full Text] [Related]  

  • 28. Erlotinib in patient with non-small cell lung cancer: significant symptomatic improvement within a few days but without change in chest X-ray.
    Garfield D; Kashef G
    Lung Cancer; 2006 Mar; 51(3):389-90. PubMed ID: 16359750
    [No Abstract]   [Full Text] [Related]  

  • 29. High-dose erlotinib for refractory brain metastases in a patient with relapsed non-small cell lung cancer.
    Hata A; Kaji R; Fujita S; Katakami N
    J Thorac Oncol; 2011 Mar; 6(3):653-4. PubMed ID: 21317753
    [No Abstract]   [Full Text] [Related]  

  • 30. Clinical efficacy of erlotinib in patients previously treated for advanced non-small cell lung cancer.
    Zhou S; Ren S; Yan L; Zhang L; Tang L; Zhang J; Zhou C
    Respirology; 2009 Jul; 14(5):709-15. PubMed ID: 19659649
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Erlotinib for the treatment of non-small-cell lung cancer.
    Boysen M; Longson C; Stevens A
    Lancet Oncol; 2009 Jan; 10(1):15-6. PubMed ID: 19115513
    [No Abstract]   [Full Text] [Related]  

  • 32. Cytokeratin 19 fragment predicts the efficacy of epidermal growth factor receptor-tyrosine kinase inhibitor in non-small-cell lung cancer harboring EGFR mutation.
    Tanaka K; Hata A; Kaji R; Fujita S; Otoshi T; Fujimoto D; Kawamura T; Tamai K; Takeshita J; Matsumoto T; Monden K; Nagata K; Otsuka K; Nakagawa A; Tachikawa R; Otsuka K; Tomii K; Katakami N
    J Thorac Oncol; 2013 Jul; 8(7):892-8. PubMed ID: 23591159
    [TBL] [Abstract][Full Text] [Related]  

  • 33. NICE guidance on erlotinib for the maintenance treatment of non-small-cell lung cancer.
    Rinaldi F; George E; Clark P
    Lancet Oncol; 2011 Aug; 12(8):728-30. PubMed ID: 21928488
    [No Abstract]   [Full Text] [Related]  

  • 34. An inflammatory response with worsening of pleural effusion on treatment with erlotinib in non-small cell lung cancer.
    Toh CK; Lee P; Chowbay B; Goh JW; Mancer K; Tan PH
    Acta Oncol; 2007; 46(2):256-8. PubMed ID: 17453379
    [No Abstract]   [Full Text] [Related]  

  • 35. Independent review of interstitial lung disease associated with death in TRIBUTE (paclitaxel and carboplatin with or without concurrent erlotinib) in advanced non-small cell lung cancer.
    Yoneda KY; Shelton DK; Beckett LA; Gandara DR
    J Thorac Oncol; 2007 Jun; 2(6):537-43. PubMed ID: 17545850
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Erlotinib in the treatment of NSCLC: current and novel prospects from the ASCO 2006].
    Longo F; Giovanni M
    Tumori; 2006; 92(5):suppl 13-22. PubMed ID: 17168450
    [No Abstract]   [Full Text] [Related]  

  • 37. Safety of concomitant administration of seasonal and/or H1N1 flu vaccination in patients receiving erlotinib for advanced non-small cell lung cancer.
    Spitaleri G; Delmonte A; Toffalorio F; De Pas TM; Gregorc V
    J Thorac Oncol; 2010 May; 5(5):752-4. PubMed ID: 20421772
    [No Abstract]   [Full Text] [Related]  

  • 38. Management of EGFR mutated nonsmall cell lung carcinoma patients.
    Grigoriu B; Berghmans T; Meert AP
    Eur Respir J; 2015 Apr; 45(4):1132-41. PubMed ID: 25700389
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Maintenance treatment of non-small cell lung cancer].
    Hansen O; Schytte T
    Ugeskr Laeger; 2010 Mar; 172(12):954. PubMed ID: 20334788
    [No Abstract]   [Full Text] [Related]  

  • 40. Survival outcomes in patients with advanced non-small cell lung cancer treated with erlotinib: expanded access programme data from Belgium (the TRUST study).
    Van Meerbeeck J; Galdermans D; Bustin F; De Vos L; Lechat I; Abraham I
    Eur J Cancer Care (Engl); 2014 May; 23(3):370-9. PubMed ID: 24152297
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.